PREVIOUS QUESTION:

 

NEXT QUESTION:

 

What checkpoint inhibitor drugs treat metastatic bladder cancer?

ANSWER

Several immunotherapy drugs treat metastatic bladder cancer. They’re called checkpoint inhibitors.

The FDA has approved several checkpoint inhibitors for advanced bladder cancer that has gotten worse during or after chemotherapy. These include:

These drugs are given every 2-3 weeks by infusion (IV) into a vein.

  • Atezolizumab (Tecentriq)
  • Avelumab (Bavencio)
  • Durvalumab (Imfinzi)
  • Nivolumab (Opdivo)
  • Pembrolizumab (Keytruda)

SOURCES:

National Cancer Institute: “FDA Approves New Immunotherapy Drug for Bladder Cancer,” “Immunotherapy.”

Memorial Sloan Kettering Cancer Center: “Immunotherapy,” “FDA Approves ‘Game Changer’ Immunotherapy Drug for Bladder Cancer,” “A Phase II Study Assessing Mediators of Response to Nivolumab and Ipilimumab Immunotherapy in Patients with Advanced Melanoma or Bladder Cancer,” A Phase I/IB Study of Immunotherapy with CPI-444 Alone and with Atezolizumab in Patients with Metastatic Solid Tumors.”

American Cancer Society: “FDA Approves New Immunotherapy Drug for Bladder Cancer,” “Immunotherapy for bladder cancer.”

The University of Texas MD Anderson Cancer Center: “Q&A Understanding Immunotherapy,” “Nivolumab immunotherapy helps patients with advanced bladder cancer,” “Immune checkpoint inhibitors shrink tumors in 26 to 38 percent of metastatic bladder cancer patients.”

American Society of Clinical Oncology: “Patients With Advanced Bladder Cancer Benefit From Anti-PD-L1 Immunotherapy.”

The Lancet: “Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.”

FDA: “Nivolumab for Treatment of Urothelial Carcinoma.”

Reviewed by Laura J. Martin on March 3, 2019

SOURCES:

National Cancer Institute: “FDA Approves New Immunotherapy Drug for Bladder Cancer,” “Immunotherapy.”

Memorial Sloan Kettering Cancer Center: “Immunotherapy,” “FDA Approves ‘Game Changer’ Immunotherapy Drug for Bladder Cancer,” “A Phase II Study Assessing Mediators of Response to Nivolumab and Ipilimumab Immunotherapy in Patients with Advanced Melanoma or Bladder Cancer,” A Phase I/IB Study of Immunotherapy with CPI-444 Alone and with Atezolizumab in Patients with Metastatic Solid Tumors.”

American Cancer Society: “FDA Approves New Immunotherapy Drug for Bladder Cancer,” “Immunotherapy for bladder cancer.”

The University of Texas MD Anderson Cancer Center: “Q&A Understanding Immunotherapy,” “Nivolumab immunotherapy helps patients with advanced bladder cancer,” “Immune checkpoint inhibitors shrink tumors in 26 to 38 percent of metastatic bladder cancer patients.”

American Society of Clinical Oncology: “Patients With Advanced Bladder Cancer Benefit From Anti-PD-L1 Immunotherapy.”

The Lancet: “Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.”

FDA: “Nivolumab for Treatment of Urothelial Carcinoma.”

Reviewed by Laura J. Martin on March 3, 2019

NEXT QUESTION:

What is transurethral resection (TUR) surgery for bladder cancer?

WAS THIS ANSWER HELPFUL

THIS TOOL DOES NOT PROVIDE MEDICAL ADVICE. It is intended for general informational purposes only and does not address individual circumstances. It is not a substitute for professional medical advice, diagnosis or treatment and should not be relied on to make decisions about your health. Never ignore professional medical advice in seeking treatment because of something you have read on the WebMD Site. If you think you may have a medical emergency, immediately call your doctor or dial 911.

    This tool does not provide medical advice. See additional information.

    Other Answers On: